Pancreatic ductal adenocarcinoma (PDA) remains one of the most aggressive tumors in humans. A notable feature of PDA is its innate resistance to many chemotherapies. In preclinical studies, Abraxane showed antitumor activity as a single agent and synergistic activity in combination with gemcitabine in murine models of pancreatic cancer. In this study, we have developed and characterized multiple models of patient derived xenograft (PDX) pancreatic models. These models recapitulate major structural and genetic features noted in patient populations. Developed PDX models are from both prior treated and non prior treated patients with varying levels of resistance to Gemcitibine. Here we have investigated efficacy of standard of care agents in these pancreatic models and demonstrate the potential utility of the pancreatic models in drug discovery efforts in oncology for the treatment of pancreatic cancer.

Citation Format: Jill Ricono, Jayant Thatte, Colleen Scott, Thomas B. Broudy. Development of patient-derived xenograft (PDX) models for pancreatic carcinoma as a preclinical platform for drug development. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5185.